Results 51 to 60 of about 944,744 (294)
Passive immunotherapy against Aβ in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage [PDF]
, 2004 BACKGROUND: Anti-Aβ immunotherapy in transgenic mice reduces both diffuse and compact amyloid deposits, improves memory function and clears early-stage phospho-tau aggregates.
Freeman, Melissa J +6 more
core +3 more sources
OncoImmunology, 2018 Memory CD8+ T cell responses have the potential to mediate long-lasting protection against cancers. Resident memory CD8+ T (Trm) cells stably reside in non-lymphoid tissues and mediate superior innate and adaptive immunity against pathogens.
Felipe Gálvez-Cancino +13 more
doaj +1 more source
Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again
Genome Medicine, 2018 For at least 300 years the immune system has been targeted to improve human health. Decades of work advancing immunotherapies against infection and autoimmunity paved the way for the current explosion in cancer immunotherapies.
Samantha L. Bucktrout +2 more
doaj +1 more source
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
Journal of experimental & clinical cancer research : CR, 2022 Adoptive cell therapy with chimeric antigen receptor (CAR) immunotherapy has made tremendous progress with five CAR T therapies approved by the US Food and Drug Administration for hematological malignancies.
K. Pan +5 more
semanticscholar +1 more source
Immunotherapy of lymphomas [PDF]
Journal of Clinical Investigation, 2020 Lymphoid malignancies typically promote an infiltrate of immune cells at sites involved by the disease. While some of the immune cells present in lymphoma have effector function, the immune system is unable to eradicate the malignant clone. Therapies that optimize immune function therefore have the potential to improve the outcome of lymphoma patients.
Yi Lin, Stephen M. Ansell
openaire +2 more sources
Novel Characterization of Myeloid-Derived Suppressor Cells in Tumor Microenvironment
Frontiers in Cell and Developmental Biology, 2021 Myeloid-derived suppressor cells (MDSCs) are a heterogeneous group of cells generated in various pathologic conditions, which have been known to be key components of the tumor microenvironment (TME) involving in tumor immune tolerance. So MDSCs have been
Yanan Li +5 more
doaj +1 more source
Parameter estimation and treatment optimization in a stochastic model for immunotherapy of cancer [PDF]
, 2020 Adoptive Cell Transfer therapy of cancer is currently in full development and mathematical modeling is playing a critical role in this area. We study a stochastic model developed by Baar et al.
Coquille, Loren +2 more
core +1 more source
Cancer Biology & Therapy, 2014 Immunotherapy is a cornerstone in the treatment of melanoma, and is intended to modulate the host immunity against the tumor. Immunotherapy can be used in an adjuvant setting, after complete surgical excision in patients with a high risk of disease relapse and as a treatment in advanced (unresectable or metastatic) stages.
SANLORENZO, Martina +12 more
openaire +5 more sources
ERAP1 overexpression in HPV-induced malignancies: A possible novel immune evasion mechanism
OncoImmunology, 2017 Immune evasion of tumors poses a major challenge for immunotherapy. For human papillomavirus (HPV)-induced malignancies, multiple immune evasion mechanisms have been described, including altered expression of antigen processing machinery (APM) components.
Alina Steinbach +9 more
doaj +1 more source
Natural killer cells in antitumour adoptive cell immunotherapy
Nature Reviews. Cancer, 2022 Natural killer (NK) cells comprise a unique population of innate lymphoid cells endowed with intrinsic abilities to identify and eliminate virally infected cells and tumour cells.
Tamara J Laskowski +2 more
semanticscholar +1 more source